NCT02430545 - Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Healthy Volunteers

Interventions

DRUG

Glasdegib

Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin

DRUG

Rifampin

Subjects receive rifampin 600 mg oral dose daily \[Day -6 to day 4\]

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven